论著

伴卡梅现象儿童血管瘤36例临床特点及治疗分析

  • 黄世浩 ,
  • 袁晓军
展开
  • 上海交通大学医学院附属新华医院儿血液肿瘤科(上海 200092)

收稿日期: 2023-12-20

  网络出版日期: 2024-11-08

Analysis on clinical characteristics and treatment for Kasabach-Merritt phenomenon in 36 children with hemangioma

  • Shihao HUANG ,
  • Xiaojun YUAN
Expand
  • Department of Pediatric Hematology/Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2023-12-20

  Online published: 2024-11-08

摘要

目的 分析具有卡梅现象的儿童血管瘤患者的临床特点,总结治疗经验。方法 回顾性分析2006年4月1日至2021年12月31日就诊的伴有卡梅现象的儿童血管瘤患者的临床资料。结果 共36例血管瘤儿童伴有卡梅现象,占同期血管瘤就诊患儿的0.6%。5例(13.9%)患儿在发病早期出现典型卡梅现象,26例(72.2%)肿块位置浅表,瘤体小,4例(11.1%)肿块位于组织深部,瘤体相对较大,1例(2.8%)以便血为首发症状,肿块未被发现。中位随访时间为86个月。所有患儿确诊时中位血小板计数为24.5(11.8~43.5)×109/L,治疗后恢复至168.0(101.8~314.5)×109/L。24例接受综合治疗的患儿均获得完全缓解;12例接受单一治疗的患儿中,5例获得完全缓解,3例部分缓解,4例治疗无效。所有患儿的总体完全缓解率为80.6%,部分缓解率为8.3%,无效率为11.1%;7年总体生存率为88.9%,病死率为11.1%。结论 症状隐匿是卡梅现象发病的早期特点。瘤体进行性增大或伴有其他出凝血异常症状的血管瘤患者,需尽早完善相关实验室检查。

本文引用格式

黄世浩 , 袁晓军 . 伴卡梅现象儿童血管瘤36例临床特点及治疗分析[J]. 临床儿科杂志, 2024 , 42(11) : 917 -921 . DOI: 10.12372/jcp.2024.23e1206

Abstract

Objective To analyze the clinical characteristics of pediatric hemangioma patients with Kasabach-Merritt phenomenon (KMP), and sum up its treatment experience. Methods The clinical data of children with KMP diagnosed from April 1, 2006 to December 31, 2021 were retrospectively analyzed. Results A total of 36 children with hemangioma were accompanied by KMP, accounting for 0.6% of the children with hemangioma. Five patients (13.9%) showed typical clinical manifestations of KMP in the early stage of the disease; 26 patients (72.2%) had superficial tumors with small lesions; 4 patients (11.1%) had deep-seated tumors with relatively larger lesions; 1 patient (2.8%) presented with hematochezia as the initial symptom, and the tumor was not detected. Median follow-up time was 86 months. All patients manifested thrombocytopenia at the time of diagnosis and the median platelet counts were 24.5(11.8-43.5)×109/L, which increased to 168.0(101.8-314.5)×109/L after treatment. Twenty-four patients (66.7%) received combined therapy, all of them got complete remission (CR). Twelve patients (33.3%) received monotherapy, of them, five patients got CR, three got partial remission (PR), four showed no response. The overall CR rate was 80.6%, PR rate was 8.3%, and NR rate was 11.1%. The 7-year overall survival rate was 88.9% and the fatality rate was 11.1%. Conclusions The masking of symptom was the characteristics of KMP. Appropriate laboratory testing should be performed as soon as possible for patients with dysfunction of blood coagulation or rapidly progressive hemangiomas.

参考文献

[1] Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case[J]. Arch Pediatr Adolesc Med, 1940, 59: 1063-1070.
[2] Huo J, Chen S, Li J, et al. Retroperitoneal kaposiform hemangioendothelioma with kasabach-merritt phenomenon in children: a case report and review of the literature[J]. Front Pediatr, 2023, 11: 1138689.
[3] Maza-Morales M, Valdés-Loperena S, Durán-McKinster LC, et al. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review[J]. Pediatr Dermatol, 2023, 40(3): 440-445.
[4] Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform heman-gioendothelioma: a randomized clinical trial[J]. Blood, 2022, 139(11): 1619-1630.
[5] Zhou J, Li Y, Qiu T, et al. Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges[J]. Int J Cancer, 2023, 153(3): 600-608.
[6] Wang L, Li J, Wu C, et al. Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma[J]. Front Pediatr, 2022, 10: 949950.
[7] Yao W, Li KL, Qin ZP, et al. Standards of care for Kasabach-Merritt phenomenon in China[J]. World J Pediatr, 2021, 17(2): 123-130.
[8] 中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J]. 中华儿科杂志, 2021, 59(10): 810-819.
[9] Helligs? L, Mikkelsen TS, Hvas AM. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon in an infant girl[J]. Clin Case Rep, 2023, 11(9): e7859.
[10] Hu Y, Song D, Wu C, et al. Clinical and imaging features of Kaposiform hemangioendothelioma in infants[J]. Heliyon, 2023, 9(5): e15425.
[11] Zhao Y, Legan CE. Liver transplantation for giant hemangioma complicated by Kasabach-Merritt syndrome: a case report and literature review[J]. Am J Case Rep, 2022, 23: e936042.
[12] Zhang L, Liu L, Luo H, et al. Combination therapy for pediatric patients with Kasabach-Merritt phenomenon: a single-center retrospective study[J]. Medicine (Baltimore), 2022, 101(34): e30296.
[13] Yan Z, Ji C. Medical and interventional therapy of Kasabach-Merritt phenomenon associated with Kaposiform hemangioendothelioma: a case report[J]. Case Reports, 2023, 6(3): 130-133.
[14] Yin CG, Qi WW, Wang S, et al. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach-Merritt phenomenon in infants, a retrospective study[J]. Ann Med, 2023, 55(1):2196090.
文章导航

/